Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Payables: 2010-2024

Historic Payables for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $211,000.

  • Altimmune's Payables rose 324.01% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 28.06%. This contributed to the annual value of $211,000 for FY2024, which is 89.81% down from last year.
  • As of FY2024, Altimmune's Payables stood at $211,000, which was down 89.81% from $2.1 million recorded in FY2023.
  • Over the past 5 years, Altimmune's Payables peaked at $4.8 million during FY2022, and registered a low of $211,000 during FY2024.
  • For the 3-year period, Altimmune's Payables averaged around $2.4 million, with its median value being $2.1 million (2023).
  • Its Payables has fluctuated over the past 5 years, first spiked by 3,258.34% in 2020, then tumbled by 89.81% in 2024.
  • Altimmune's Payables (Yearly) stood at $612,293 in 2020, then skyrocketed by 232.19% to $2.0 million in 2021, then skyrocketed by 136.18% to $4.8 million in 2022, then crashed by 56.91% to $2.1 million in 2023, then slumped by 89.81% to $211,000 in 2024.